Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma
NCT ID: NCT05798897
Last Updated: 2025-08-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
79 participants
Study Classification
INTERVENTIONAL
Study Start Date
2023-01-02
Study Completion Date
2028-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
NCT00452127
Non-Hodgkin's Lymphoma
TERMINATED
PHASE1/PHASE2
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
+34 more
COMPLETED
PHASE1/PHASE2
506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma
NCT00005950
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
+7 more
TERMINATED
PHASE2
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
NCT00481832
Lymphoma, Non-Hodgkin
TERMINATED
PHASE2
HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
NCT05190068
B-Cell Non-Hodgkin's Lymphoma
COMPLETED
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is a Phase 1, multicenter, open-label study designed to evaluate the safety and efficacy of MT-601 in participants with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) who either relapsed or had incomplete response after cluster of differentiation (CD) 19-directed chimeric antigen receptor (CAR) T cell therapy or are CAR T cell therapy naïve (ineligible or refused CD19-directed CAR T cell therapy or for whom CAR T cell therapy is not available). The study will consist of two portions or phases: 1) Dose Escalation with allowance for backfilling cohorts (up to 50 participants) followed by 2) Dose Expansion at the preliminary RP2DS in 1-2 disease specific cohorts of up to 29 participants each. The Dose Expansion portion of this study will begin after completion of the Dose Escalation portion. The purpose of the Dose Expansion portion of the study is to evaluate the clinical efficacy of MT-601 at the dose determined to be safe in the Dose Escalation portion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Non-Hodgkin Lymphoma, Adult
Non-Hodgkin Lymphoma, Refractory
Non-Hodgkin Lymphoma, Relapsed
Non Hodgkin Lymphoma
Hodgkin Lymphoma
Hodgkin Lymphoma, Adult
Hodgkin's Lymphoma, Relapsed, Adult
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Single Arm Study
Single arm study evaluating MT-601 investigational product at 200 million cells and 400 million cells per dose
Group Type
EXPERIMENTAL
MT-601
Intervention Type
DRUG
Multi-antigen specific CD4+ andCD8+ T cells
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MT-601
Multi-antigen specific CD4+ andCD8+ T cells
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria apply and the participant, in the judgement of the Investigator, is an appropriate candidate for experimental therapy:
General:
1. Participant must be ≥ 18 years of age and capable of giving signed informed consent (ICF), which includes compliance with the requirements and restrictions listed in the ICF and in the protocol, at the time of signing the ICF.
Disease Specific:
2. Cytologically or histologically confirmed diagnosis of NHL, HL or CLL based on the 2022 World Health Organization (WHO) criteria for hematolymphoid neoplasms
3. Enrollment of the following subtypes will be eligible:
1. LBCL including diffuse large B cell lymphoma, primary mediastinal B cell lymphoma (PMBCL), high grade B cell lymphoma (HGBL), T cell rich B cell lymphoma and transformed indolent lymphoma (transformed iNHL)
2. FL
3. MCL
4. MZL
5. HL
The following additional subtypes may be enrolled in disease specific cohorts during Dose Expansion (upon approval by Sponsor)
6. CLL/SLL
7. CNS lymphoma
8. CAR T cell refractory
4. Must have measurable disease as per 2014 Lugano criteria or 2018 iwCLL criteria. Participants with splenic MZL must have measurable splenomegaly on imaging or evidence of bone marrow involvement.
Prior Treatments
5. Participants who are R/R, are intolerant to, or are considered ineligible for systemic standard of care anticancer treatments, including at least 2 prior therapies. Participants who refuse standard of care treatments may also be considered if documentation is provided that he/she has been made aware of all therapeutic options.
6. For participants with LBCL, FL, and MCL: Have received CD19-directed CAR T cell therapy and relapsed ≥ 30 days or attained an incomplete response as the best response within 1 year after CAR T cell administration. Participants who refuse or are ineligible for CAR T cell therapy are eligible for this study. Note: during Dose Expansion, a specific cohort may be enrolled to evaluate participants who were refractory to CD19-directed CAR T cell therapy.
Health Status
7. Karnofsky score of ≥70 or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
8. Life expectancy ≥12 weeks
9. Adequate blood, liver, renal and cardiac function:
1. Hematology: Hemoglobin ≥ 7.0 g/dL (can be transfused), absolute lymphocyte count (ALC) ≥ 300/μL, (prior to apheresis only), absolute neutrophil count (ANC) ≥ 750/μL and platelet count ≥ 50,000/μL (prior to the conditioning regimen only)
2. Liver: Bilirubin ≤ 1.5X upper limit of normal (ULN) (exception of bilirubin elevation due to Gilbert's syndrome 3X); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3X ULN
3. Renal: Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL/min (prior to the conditioning regimen)
4. Cardiac: left ventricular ejection fraction ≥ 45% (prior to the leukapheresis) Sex
10. Female: Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (i.e., with a failure rate of \< 1% per year), preferably with low user dependency during the intervention period and for at least 6 months after the last infusion of MT-601 and agrees not to donate eggs (i.e., ova and oocytes) for the purpose of reproduction during this period
11. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 6 months after the last infusion of MT-601:
Refrain from donating sperm
PLUS either:
Be abstinent from intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use a male condom AND should also be advised of the benefit for a nonpregnant female partner to use a highly effective method of contraception as a condom may break or leak
* Patients are excluded from the study if any of the following criteria apply:
Disease-related
1. Evidence of bulky disease at the time of the conditioning regimen (≥ 10 cm in diameter for LBCL or HL and \> 6 cm for other subtypes)
2. Untreated or ongoing treatment for CNS lymphoma or completed treatment within 2 weeks of apheresis (Note: May be allowed in Dose Expansion if disease specific cohort for CNS lymphoma is opened)
3. Refractory to CAR T therapy defined as a best response of stable disease or disease progression (Note: May be allowed in Dose Expansion if disease specific cohort for CAR T cell therapy refractory is opened)
4. Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression Medical Conditions
5. Primary immunodeficiency
6. Severe or uncontrolled autoimmune disorder
7. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
8. Unresolved immune effector cell-associated neurotoxicity syndrome (ICANS) from prior CAR T cell administration. Consideration for Grade 1 may be made after discussion with the Medical Monitor
9. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast, and/or prostate) unless disease free for at least 3 years
10. Cardiac conditions:
1. Medically uncontrolled hypertension (≥ 160 mmHg systolic blood pressure or ≥ 100 mmHg diastolic blood pressure)
2. Congestive heart failure Class ≥ II as defined by the New York Heart Association
3. Acute coronary syndrome (including unstable angina, coronary artery stenting, or angioplasty, bypass grafting within prior 6 months)
4. History or evidence of current, uncontrolled, clinically significant, unstable arrhythmias
11. Oxygen saturation at room air \< 92%
12. Participant has known human immunodeficiency virus (HIV) infection, or active hepatitis B virus (HBV)/hepatitis C virus (HCV) infection
13. Acute bacterial, viral, fungal infection requiring systemic therapy (uncomplicated urinary tract infection and bacterial pharyngitis are permitted if responding to therapy)
14. History of severe allergic reactions to any of the study intervention components including conditioning regimen, dimethyl sulfoxide (DMSO) or to tocilizumab
15. Clinically significant reversible toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline
* Participants with Grade 2 neuropathies due to prior treatment will be allowed on study.
* Participants with clinical nonsignificant toxicities, such as alopecia, will be allowed on study.
Prior/Concomitant Therapy
Prior to Apheresis:
16. Receipt of allogeneic hematopoietic cell transplant (HCT) within 12 months; on immunosuppression or with evidence of donor/mixed chimera
17. Receipt of autologous HCT within 3 months
18. Treatment with CD19-directed CAR T cell therapy within 3 months
19. Treatment with bispecific antibody within 1 month
20. Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
21. Treatment with monoclonal antibodies impacting T cell function within 14 days
22. Treatment with systemic immunosuppression including systemic corticosteroids (unless ≤5 mg/day oral prednisone or steroid equivalent) within 14 days
23. Treatment with chemotherapy within 7 days
Prior to the conditioning regimen:
24. Treatment with a live, attenuated vaccine within 4 weeks
25. Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
26. Treatment with chemotherapy or biologics/monoclonal antibodies within 14 days
27. Treatment with radiation therapy within 7 days
28. Treatment with a tyrosine kinase inhibitor (TKI) within 7 days or 5 half-lives (whichever is longer) before conditioning regimen
29. Hematopoietic growth factors \<2 days
At either time:
30. Treatment with experimental CAR T cell product unless approved by Medical Monitor
31. Treatment with other cancer therapy including investigational agents that do not fit in the above categories within 14 days
32. Major surgery within 14 days
Other
33. Pregnant or lactating
34. Any other issue which, in the opinion of the treating physician, would make the participant ineligible for the study
General:
1. Participant must be ≥ 18 years of age and capable of giving signed informed consent (ICF), which includes compliance with the requirements and restrictions listed in the ICF and in the protocol, at the time of signing the ICF.
Disease Specific:
2. Cytologically or histologically confirmed diagnosis of NHL, HL or CLL based on the 2022 World Health Organization (WHO) criteria for hematolymphoid neoplasms
3. Enrollment of the following subtypes will be eligible:
1. LBCL including diffuse large B cell lymphoma, primary mediastinal B cell lymphoma (PMBCL), high grade B cell lymphoma (HGBL), T cell rich B cell lymphoma and transformed indolent lymphoma (transformed iNHL)
2. FL
3. MCL
4. MZL
5. HL
The following additional subtypes may be enrolled in disease specific cohorts during Dose Expansion (upon approval by Sponsor)
6. CLL/SLL
7. CNS lymphoma
8. CAR T cell refractory
4. Must have measurable disease as per 2014 Lugano criteria or 2018 iwCLL criteria. Participants with splenic MZL must have measurable splenomegaly on imaging or evidence of bone marrow involvement.
Prior Treatments
5. Participants who are R/R, are intolerant to, or are considered ineligible for systemic standard of care anticancer treatments, including at least 2 prior therapies. Participants who refuse standard of care treatments may also be considered if documentation is provided that he/she has been made aware of all therapeutic options.
6. For participants with LBCL, FL, and MCL: Have received CD19-directed CAR T cell therapy and relapsed ≥ 30 days or attained an incomplete response as the best response within 1 year after CAR T cell administration. Participants who refuse or are ineligible for CAR T cell therapy are eligible for this study. Note: during Dose Expansion, a specific cohort may be enrolled to evaluate participants who were refractory to CD19-directed CAR T cell therapy.
Health Status
7. Karnofsky score of ≥70 or performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
8. Life expectancy ≥12 weeks
9. Adequate blood, liver, renal and cardiac function:
1. Hematology: Hemoglobin ≥ 7.0 g/dL (can be transfused), absolute lymphocyte count (ALC) ≥ 300/μL, (prior to apheresis only), absolute neutrophil count (ANC) ≥ 750/μL and platelet count ≥ 50,000/μL (prior to the conditioning regimen only)
2. Liver: Bilirubin ≤ 1.5X upper limit of normal (ULN) (exception of bilirubin elevation due to Gilbert's syndrome 3X); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3X ULN
3. Renal: Serum creatinine ≤ 1.5X ULN or measured or calculated creatinine clearance ≥ 50 mL/min (prior to the conditioning regimen)
4. Cardiac: left ventricular ejection fraction ≥ 45% (prior to the leukapheresis) Sex
10. Female: Is a woman of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (i.e., with a failure rate of \< 1% per year), preferably with low user dependency during the intervention period and for at least 6 months after the last infusion of MT-601 and agrees not to donate eggs (i.e., ova and oocytes) for the purpose of reproduction during this period
11. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 6 months after the last infusion of MT-601:
Refrain from donating sperm
PLUS either:
Be abstinent from intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR Must agree to use a male condom AND should also be advised of the benefit for a nonpregnant female partner to use a highly effective method of contraception as a condom may break or leak
* Patients are excluded from the study if any of the following criteria apply:
Disease-related
1. Evidence of bulky disease at the time of the conditioning regimen (≥ 10 cm in diameter for LBCL or HL and \> 6 cm for other subtypes)
2. Untreated or ongoing treatment for CNS lymphoma or completed treatment within 2 weeks of apheresis (Note: May be allowed in Dose Expansion if disease specific cohort for CNS lymphoma is opened)
3. Refractory to CAR T therapy defined as a best response of stable disease or disease progression (Note: May be allowed in Dose Expansion if disease specific cohort for CAR T cell therapy refractory is opened)
4. Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression Medical Conditions
5. Primary immunodeficiency
6. Severe or uncontrolled autoimmune disorder
7. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
8. Unresolved immune effector cell-associated neurotoxicity syndrome (ICANS) from prior CAR T cell administration. Consideration for Grade 1 may be made after discussion with the Medical Monitor
9. History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast, and/or prostate) unless disease free for at least 3 years
10. Cardiac conditions:
1. Medically uncontrolled hypertension (≥ 160 mmHg systolic blood pressure or ≥ 100 mmHg diastolic blood pressure)
2. Congestive heart failure Class ≥ II as defined by the New York Heart Association
3. Acute coronary syndrome (including unstable angina, coronary artery stenting, or angioplasty, bypass grafting within prior 6 months)
4. History or evidence of current, uncontrolled, clinically significant, unstable arrhythmias
11. Oxygen saturation at room air \< 92%
12. Participant has known human immunodeficiency virus (HIV) infection, or active hepatitis B virus (HBV)/hepatitis C virus (HCV) infection
13. Acute bacterial, viral, fungal infection requiring systemic therapy (uncomplicated urinary tract infection and bacterial pharyngitis are permitted if responding to therapy)
14. History of severe allergic reactions to any of the study intervention components including conditioning regimen, dimethyl sulfoxide (DMSO) or to tocilizumab
15. Clinically significant reversible toxicities from prior cancer therapy that have not recovered to Grade 1 or baseline
* Participants with Grade 2 neuropathies due to prior treatment will be allowed on study.
* Participants with clinical nonsignificant toxicities, such as alopecia, will be allowed on study.
Prior/Concomitant Therapy
Prior to Apheresis:
16. Receipt of allogeneic hematopoietic cell transplant (HCT) within 12 months; on immunosuppression or with evidence of donor/mixed chimera
17. Receipt of autologous HCT within 3 months
18. Treatment with CD19-directed CAR T cell therapy within 3 months
19. Treatment with bispecific antibody within 1 month
20. Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
21. Treatment with monoclonal antibodies impacting T cell function within 14 days
22. Treatment with systemic immunosuppression including systemic corticosteroids (unless ≤5 mg/day oral prednisone or steroid equivalent) within 14 days
23. Treatment with chemotherapy within 7 days
Prior to the conditioning regimen:
24. Treatment with a live, attenuated vaccine within 4 weeks
25. Treatment with antibody drug conjugates (ADC's) or PD-1/PD-L1 within 21 days
26. Treatment with chemotherapy or biologics/monoclonal antibodies within 14 days
27. Treatment with radiation therapy within 7 days
28. Treatment with a tyrosine kinase inhibitor (TKI) within 7 days or 5 half-lives (whichever is longer) before conditioning regimen
29. Hematopoietic growth factors \<2 days
At either time:
30. Treatment with experimental CAR T cell product unless approved by Medical Monitor
31. Treatment with other cancer therapy including investigational agents that do not fit in the above categories within 14 days
32. Major surgery within 14 days
Other
33. Pregnant or lactating
34. Any other issue which, in the opinion of the treating physician, would make the participant ineligible for the study
Minimum Eligible Age
18 Years
Maximum Eligible Age
100 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Marker Therapeutics, Inc.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
City of Hope
Duarte, California, United States
Site Status
RECRUITING
University of Colorado
Aurora, Colorado, United States
Site Status
RECRUITING
Colorado Blood Cancer Institute (Sarah Cannon)
Denver, Colorado, United States
Site Status
RECRUITING
University of Kansas Medical Center
Kansas City, Kansas, United States
Site Status
RECRUITING
Cornell
New York, New York, United States
Site Status
RECRUITING
Sarah Cannon Research Institute at St. David's South Austin
Austin, Texas, United States
Site Status
RECRUITING
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
United States
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mariah Endres
Role: primary
608-262-7657
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRKR-22-601-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
506U78 in Treating Patients With Lymphoma
NCT00005080
COMPLETED
PHASE2
Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)
NCT05155839
UNKNOWN
PHASE1
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
NCT03939026
COMPLETED
PHASE1
An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma
NCT05315713
TERMINATED
PHASE1/PHASE2
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
NCT05784441
ACTIVE_NOT_RECRUITING
PHASE1
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
NCT06018129
TERMINATED
PHASE1/PHASE2
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438
RECRUITING
PHASE1
Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
NCT03682796
COMPLETED
PHASE1
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
NCT00131937
COMPLETED
PHASE2
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
NCT05721222
TERMINATED
PHASE1/PHASE2
Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies
NCT01799889
TERMINATED
PHASE2
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
NCT00005803
COMPLETED
PHASE1/PHASE2
506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
NCT00005982
TERMINATED
PHASE2
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
NCT01258998
COMPLETED
PHASE2
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00014664
UNKNOWN
PHASE2
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)
NCT04416984
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
S9911, Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003784
COMPLETED
PHASE2
A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma
NCT06561425
RECRUITING
PHASE1/PHASE2
APG-1252 Monotherapy or in Combination With Other Therapeutic Agent in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT05186012
RECRUITING
PHASE1/PHASE2
Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma
NCT00606645
COMPLETED
PHASE1
A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
NCT02453087
COMPLETED
PHASE1
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
NCT00059995
COMPLETED
PHASE1/PHASE2
A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas
NCT02875223
TERMINATED
PHASE1
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
NCT03369964
WITHDRAWN
PHASE1
Monoclonal Antibody Therapy in Treating Patients With Recurrent Hodgkin's Lymphoma
NCT00055783
COMPLETED
PHASE2